

# CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised

- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain Manhattan, Live
- Canine parvovirus, strain Cornell 780916, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Canine distemper virus, strain Lederle, Live

## Product identification

### **Medicine name:**

CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

### **Active substance:**

Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain Manhattan, Live

Canine parvovirus, strain Cornell 780916, Live

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Canine distemper virus, strain Lederle, Live

---

**Target species:**

Dog

---

**Route of administration:**

Subcutaneous use

---

## Product details

**Active substance and strength:**

Canine adenovirus 2, strain Manhattan, Live

10000.00 50% cell culture infectious dose / 1.00 Dose

Canine parainfluenza virus, strain Manhattan, Live

100000.00 50% cell culture infectious dose / 1.00 Dose

Canine parvovirus, strain Cornell 780916, Live

100000.00 50% cell culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

4250.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

4350.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Canine distemper virus, strain Lederle, Live

1000.00 50% cell culture infectious dose / 1.00 Dose

---

**Pharmaceutical form:**

Lyophilisate and suspension for suspension for injection

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QI07AI02

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Denmark

---

**Available in:**

Denmark

---

**Package description:**

1 vial of lyophilisate and 1 vial of suspension

100 vials of lyophilisate and 100 vials of suspension

50 vials of lyophilisate and 50 vials of suspension

25 vials of lyophilisate and 25 vials of suspension

10 vials of lyophilisate and 10 vials of suspension

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Virbac

---

**Marketing authorisation date:**

14/03/2016

---

**Manufacturing sites for batch release:**

Virbac

---

**Responsible authority:**

Danish Medicines Agency

---

**Authorisation number:**

56357

---

**Date of authorisation status change:**

14/03/2016

---

**Reference member state:**

France

---

**Procedure number:**

FR/V/0237/001

---

**Concerned member states:**

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland  
Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg  
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain  
Sweden United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

eu-puar-frv0237001-mr-rpe312-en.pdf